Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01414283 · ClinicalTrials.gov registry record · Phase 1
Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer
A Phase 1 study, sponsored by Progenics Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT01414283: Completed Phase 1 study, sponsored by Progenics Pharmaceuticals.
NCT01414283 is a Phase 1 study that has completed, run by Progenics Pharmaceuticals. The registered enrollment target is 52 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (13% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01414283, a Phase 1 study, has completed, sponsored by Progenics Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
Prostate-specific Membrane Antigen Antibody-Drug Conjugate (PSMA ADC) 1301 is an open-label, dose-escalation phase 1 study of PSMA ADC administered IV in subjects with progressive, castration-resistant, metastatic prostate cancer that has progressed after prior taxane therapy. For all subjects, PSMA ADC will be administered in four repeating cycles.
Interventions
- DRUG PSMA ADC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2008-10 |
| Est. Completion | 2013-09 |
| Phase | Phase 1 |
What the finished NCT01414283 record still lists
NCT01414283 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (13% lower).
The record links to 0 conditions, and to 1 intervention - of which PSMA ADC is the first listed.
NCT01414283 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01414283 about?
NCT01414283 is a clinical study titled "Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer". Prostate-specific Membrane Antigen Antibody-Drug Conjugate (PSMA ADC) 1301 is an open-label, dose-escalation phase 1 study of PSMA ADC administered IV in subjects with progressive, castration-resistant, metastatic prostate cancer that has progressed after prior taxane therapy. For all subjects, PSMA...
What is the current status of trial NCT01414283?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2008-10. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01414283?
The interventions under investigation include: PSMA ADC (DRUG).
Who is sponsoring clinical trial NCT01414283?
This trial is sponsored by Progenics Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01414283's enrollment target sits among peer trials
52 956th of 2000 higher than 1,032 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia